Izigaba Zokwelapha

Ukwelashwa Okuvelele

Ukwelashwa Ngegciwane Le-Oncolytic: Ukwelashwa Komdlavuza Okuthuthukisiwe

I-CAR-T ye-Glioblastoma

Umjovo we-Nusinersen Sodium: Ithemba Lokuwohloka Kwemisipha Yomgogodla

Ukwelashwa kwe-CAR-T komdlavuza wesisu

$Ukwelashwa kwe-CAR-T kwe-Relapsed/Refractory Neuroblastoma$

Ukwelashwa kwe-CAR-T kwe-Relapsed/Refractory Neuroblastoma

I-CAR-T ye-Systemic Lupus Erythematosus (SLE)

Isifo Se-Sickle Cell kanye ne-Thalassemia

Ukwelashwa Ngezakhi Zofuzo Okusha Kunikeza Ithemba Elisha Ngeziguli Ezinesifo Se-Sickle Cell Ne-Thalassemia

I-FUCASO: Ukwelashwa kwe-BCMA CAR-T okuGuquliwe okuSebenza kahle kanye nokuphepha okungenakuqhathaniswa

Ukusebenzisa Amaseli e-NK: Ukuthuthukisa Ukwelashwa Komdlavuza Ngale Kwemingcele

0102030405

Ukubuka Konke Okuphelele Kokwelashwa Okubangela Umdlavuza Wegazi

I-CAR-T Therapy, efushanisiwe nelithi Chimeric Antigen Receptor T-Cell Immunotherapy, iyindlela yokwelapha izakhi zofuzo ethuthukisiwe ehilela ukuguqula izakhi zofuzo zamaseli e-T esiguli ukuze ihlose futhi ibhubhise amaseli omdlavuza. Ngokungafani nemithi yendabuko, ukwelashwa kwe-CAR-T kwenzelwe isiguli ngasinye futhi kudinga ukuqoqa amaseli e-T egazini lesiguli ngaphambi kokuwabuyisela emzimbeni ngemva kobunjiniyela bezakhi zofuzo.

Xhumana nathi

Izinkomba ze-CAR-T

● I-B-cell acute lymphoblastic leukemia

●I-myeloma eminingi

●I-leukemia ye-lymphocytic engapheli

●I-Non-Hodgkin lymphoma

●Ukusabalalisa i-lymphoma enkulu ye-B-cell

●I-SLE (i-Systemic Lupus Erythematosus)

●I-Myasthenia gravis

●Ezinye izifo ezizimele

Ukusebenza kahle kakhulu kwezokwelapha kwe-CAR-T

Izinkomba ze-CD19+20CAR-T: Iziguli ezine-B-cell non-Hodgkin's lymphoma

Izinga le-CR lenyanga eyodwa	Izinga le-PR lenyanga eyodwa	Isilinganiso se-OR senyanga eyodwa	I-CRS≥3	I-CRES≥3
71.95% (59/82)	25.6（21/82）	97.55（80/82）	12.19% (10/82)	0

Izinkomba ze-CD19+22CAR-T: Ukwelashwa kweziguli ezine-CD19 eziphinde zabuyela emuva futhi ezingasabeli kahle i-B-lymphocytic leukemia

Izinga le-CR lenyanga eyodwa	Izinga le-PR lenyanga eyodwa	Isilinganiso se-OR senyanga eyodwa	I-CRS≥3	I-CRES≥3
92.1%（35/38）	7.9%（3/38）	100% (38/38)	15.79% (6/38)	0

Izinkomba ze-BCMACAR-T: Ukwelashwa kwe-myeloma eminingi ephinde yabuya futhi engaphikisi

Izinga le-CR lenyanga eyodwa	Izinga le-PR lenyanga eyodwa	Isilinganiso se-OR senyanga eyodwa	I-CRS≥3	I-CRES≥3
72.41% (21/29)	27.59%（8/29）	100% (29/29)	6.9% (2/29)	0

Izinzuzo Zethu

● Ukwelashwa Okuqondene Nakho: Ukwelashwa ngakunye kwe-CAR-T kwenzelwe isiguli, kuqinisekisa imiphumela yokwelashwa eqondiswe kakhulu futhi ephumelelayo.

● Izinketho Ezihlukahlukene Zokukhomba: Njengoba inezinhlobonhlobo eziningi zama-antigen aqondiwe, okuhlanganisa i-CD7, i-CD19, i-CD20, i-CD22, kanye ne-BCMA, imikhiqizo yethu ye-CAR-T inikeza ukuguquguquka okungenakuqhathaniswa ekwelapheni izifo ezahlukahlukene zegazi kanye nezifo zokuzivikela komzimba.

● Impumelelo Eqinisekisiwe Yezokwelapha: Izindlela zethu zokwelapha ze-CAR-T zibonise ukusebenza kahle okukhulu ezimweni eziningi zezokwelapha, ngamazinga okuphulukiswa okumangalisayo kanye namaphrofayili okuphepha, okuqinisa isikhundla sethu njengomholi kwezokwelapha nge-immunotherapy.

● Ukusebenza Kahle Ngezindleko Eziphezulu: Sinikeza ithuba lokuncintisana ngokwelashwa kwekhwalithi ephezulu ngamanani afinyeleleka kalula uma kuqhathaniswa neminye imikhiqizo ye-CAR-T emakethe.

● Ubuchwepheshe Obusezingeni Eliphezulu: Sisebenzisa intuthuko yakamuva kwezobunjiniyela bezakhi zofuzo, izindlela zethu zokwelapha ze-CAR-T zihlanganisa ikusasa lomdlavuza kanye nokwelashwa kwezifo ezizimele.

● Usekelo Lochwepheshe Kwezokwelapha: Ithimba lethu lodokotela nabacwaningi abanolwazi linikeza ukunakekelwa okuphelele kusukela ekubonisaneni kokuqala ngokuphathwa kokwelashwa kanye nokulandelela.

Amaseli e-CAR-T manje ayaziwa kabanzi ngokusebenza kwawo ezigulini ezingazange zisabele ekwelashweni kwendabuko njengokwelashwa ngamakhemikhali noma ukufakelwa umnkantsha. Umphakathi wezokwelapha womhlaba wonke uyaqaphela amandla amakhulu okwelashwa kwe-CAR-T ekuguquleni imiphumela yeziguli.

Izifundo namacala ahlobene nokwelashwa kwe-CAR-T

1. Ukwelashwa kwe-CAR-T kwe-Systemic Lupus Erythematosus: Ukusebenza Okumangalisayo Ecaleni Lezingane

Icala eliqavile e-Erlangen University Hospital libonise ukusebenza kahle kokwelashwa kwamaseli e-CAR-T ekwelapheni intombazane eneminyaka engu-15 ubudala ene-systemic lupus erythematosus (SLE). Ngemva kochungechunge lwezindlela zokwelapha ezihlulekile, i-Uresa yathola lokhu kwelashwa okusha ngoJuni 2023. Emasontweni amathathu ngemva kokwelashwa, izimpawu zayo zase zithuthuke kakhulu, okwaholela ekululameni okuphelele nasekubuyiselweni kokusebenza kwezinso. Le mpumelelo iphawula ukusetshenziswa kokuqala kokwelashwa kwe-CAR-T kwezifo zokuzivikela komzimba ezinganeni, okubonisa amandla ayo okufeza ukuphulukiswa kwesikhathi eside nokuguqula imiphumela yesiguli. Ucwaningo olwengeziwe luyaqhubeka ukuhlola ukusetshenziswa kwayo ezimweni ezifanayo.

https://www.bioocus.com/news/breakthrough-in-pediatric-autoimmune-disease-car-t-cell-therapy-cures-lupus-patient/

2. Ukwelashwa kwe-CAR-T kwe-Multiple Myeloma: Kutholakale Ukuthethelelwa Okubalulekile

UBjørn Simensen, isiguli esineminyaka engu-67 ubudala esivela eNorway, uthole ushintsho olukhulu empini yakhe ne-multiple myeloma (IgG lambda, ISS-II) ngemuva kokuthola ukwelashwa kweseli le-CAR-T. Ekuqaleni watholakala enesifo ngo-2017, wenza izinqubo eziningana zokwelashwa ngamakhemikhali, kodwa waphinde wabuyela emuva ngo-2021. Ngemva kokwelashwa okungasebenzi kahle, wathunyelwa eSibhedlela iLu Daopei ngoFebhuwari 2022, lapho akhethwa khona ukwelashwa kwe-CAR-T. Ngemva kokwelashwa kusengaphambili, amangqamuzana akhe e-CAR-T afakwa. Ngosuku lwama-28, ukuhlolwa kokulandelela kwembula ukuthi akukho amangqamuzana e-plasma angajwayelekile emnkantsheni wakhe wamathambo, okwaphawula impumelelo enkulu ekwelashweni kwakhe.

https://www.bioocus.com/bj-rn-simensen-multiple-myeloma-igg-lambda-iss-ii-product/

3. Ukwelashwa kwe-CD7 CAR-T kwe-T-ALL ephinde yaphela kanye ne-LBL: Ukusebenza Okuthembisayo kanye Nemiphumela

Ucwaningo lwakamuva lubonisa ukusebenza kahle kokwelashwa kwe-CD7 chimeric antigen receptor T-cell (CAR-T) kuhlanganiswe nokufakelwa kwesibili kwe-allogeneic hematopoietic stem cell (HSCT) ezigulini ezine-T-cell acute lymphoblastic leukemia (T-ALL) ephinde yatholakala kanye ne-lymphoblastic lymphoma (LBL). Okwenziwa eHebei Yanda Lu Daopei Hospital, lolu cwaningo luhilele iziguli ezingu-16 ezithole ukukhululwa okuphelele okungu-100% okuncane kakhulu kwesifo esisele (MRD)-negative ngemva kokwelashwa. Ngesilinganiso sokukhululwa okuphelele esingu-75% sezilonda zangaphandle kwe-medullary kanye namazinga okusinda okuphelele konyaka owodwa kanye namazinga okusinda angenalo i-leukemia angu-58.5% kanye no-51.4%, ngokulandelana, le ndlela entsha inikeza ithemba elisha lokukhululwa kwesikhathi eside kulezi zinhlayiya ezinolaka.

https://www.bioocus.com/news/promising-outcomes-of-cd7-car-t-therapy-combined-with-second-transplant-in-relapsed-t-all-lbl-patien/

4. Ukwelashwa kwe-CAR-T kwe-B-Cell Acute Lymphoblastic Leukemia: Ukusebenza Okungakaze Kubonwe

Ucwaningo lwamuva nje luqokomisa ukusebenza kahle okumangalisayo kokwelashwa kwe-chimeric antigen receptor-T cell (CAR-T) ekwelapheni i-B-cell acute lymphoblastic leukemia (B-ALL). Lwenziwe ngokubambisana ne-BIOOCUS kanye ne-Lu Daopei Hospital, ucwaningo lukhombisile ukuthi inani elikhulu leziguli lithole ukuphulukiswa okuphelele, okubeka ukwelashwa kwe-CAR-T njengendlela yokwelapha ehamba phambili yale leukemia enamandla. Imiphumela ethembisayo igcizelela amandla okuguqula ukwelashwa kwe-CAR-T ku-oncology, okunikeza ithemba ezigulini kanye nemindeni ebhekene ne-B-ALL. Njengoba ucwaningo luqhubeka, ukwelashwa kwe-CAR-T kulindeleke ukuthi kudlale indima ebalulekile esikhathini esizayo sokwelashwa komdlavuza.

https://www.bioocus.com/news/pioneering-car-t-therapy-in-b-cell-acute-lymphoblastic-leukemia-shows-unprecedented-efficacy/

Inqubo Yokwelapha ye-CAR-T

1. Iqoqo lamaseli e-T:

Ekuqaleni, odokotela baqoqa amaseli e-T egazini lesiguli besebenzisa inqubo ebizwa ngokuthi i-leukapheresis. Le nqubo ivame ukuthatha cishe amahora ama-4, lapho umshini wokuhlukanisa igazi uhlukanisa khona amaseli amhlophe egazi adingekayo bese ubuyisela izingxenye ezisele emzimbeni wesiguli.

2. Ukuguqulwa Nokwandiswa Kwezakhi Zofuzo:

Amaseli e-T aqoqwe athunyelwa elabhorethri ukuze aguqulwe izakhi zofuzo. Kulesi sinyathelo, amaseli e-T aklanywa ukuze ahlasele futhi abhubhise amaseli omdlavuza. Le nqubo ithatha cishe amasonto ama-2-3. Phakathi nalesi sikhathi, amaseli e-T ayavuselelwa futhi anwetshwe elabhorethri ukuqinisekisa ukusebenza kwawo ngokumelene nomdlavuza.

3. Ukufakwa Kwamaseli:

Ngemva kokuba ama-T cell aklanywe ngendlela ehlelekile esekulungele, aphinde afakwe emzimbeni wesiguli ngokufaka umjovo ngemithambo yegazi. Lesi sinyathelo sivumela amaseli omzimba aguquliwe ukuthi abone futhi aqede amaseli omdlavuza ngempumelelo.

Iziguli zingase zibe nemiphumela emibi ngesikhathi sokwelashwa, okuvame kakhulu ukuba yi-cytokine release syndrome (CRS), ebangelwa impendulo yomzimba ngesikhathi sokubhujiswa kwamangqamuzana omdlavuza asebenzayo. Nakuba i-CRS ingaba nzima kakhulu, intuthuko ekunakekelweni kwezokwelapha iye yanciphisa kakhulu izingozi zayo.

Umjikelezo wonke wokwelashwa, kusukela ekuqoqweni kwamaseli kuya ekufakweni, uvame ukuba amasonto angu-4-6, yize ubude obuqondile buxhomeke esimweni esithile sesiguli.

Ukusekelwa Okuphelele Kweziguli Zamazwe Ngamazwe Eziya E-BIOOCUS Ukuze Ziyothola Ukwelashwa Kwe-CAR-T

Kwa-BIOOCUS, sizinikele ekuhlinzekeni ukunakekelwa okuvelele kanye nokusekelwa kweziguli zamazwe ngamazwe ezifuna ukwelashwa kwe-CAR-T. Izinsizakalo zethu eziphelele zimboza zonke izinyathelo zohambo, kusukela ekulungiseleleni ngaphambi kohambo kuya ekunakekelweni kwangemva kokwelashwa.

1. Ukulungiselela Ngaphambi Kokuhamba

Ngaphambi kokuya e-BIOOCUS, iziguli zizohlolwa kusengaphambili ngemininingwane eningiliziwe esikhungweni sezokwelapha sendawo. Lokhu kuhlanganisa ukubuyekezwa okuphelele komlando wezokwelapha, ukuhlolwa ngokomzimba, kanye nokuhlolwa okufanele njengokuhlolwa kwegazi, izifundo zezithombe, kanye nokuhlolwa okuqondene nohlobo lomdlavuza olashwayo (njenge-leukemia, i-lymphoma, noma eminye imidlavuza yegazi). Siyaqinisekisa ukuthi wonke amarekhodi ezokwelapha, okuhlanganisa ukwelashwa kwangaphambilini, imiphumela yokuhlolwa, kanye nokuqinisekiswa kokuxilongwa, kuthunyelwa eqenjini lethu ukuze libuyekezwe futhi lilungiselelwe.

2. Ukuhamba Nokulaliswa Esibhedlela

Siyasiza ngazo zonke izici zokuhamba, okuhlanganisa ukuhlela indawo yokuhlala kanye nokubhukha iziguli e-BIOOCUS International Medical Center. Lapho zifika, iziguli ziqondiswa ngenqubo yokwamukelwa, okuqinisekisa ukuthi ukushintshela endaweni yokwelashwa kuhamba kahle.

3. Inqubo Yokwelapha

Uma sebengeniswe esibhedlela, iziguli zizokwenza uchungechunge lokuhlolwa kokuqala, okuhlanganisa nokuhlolwa ukuqinisekisa ukuthi ziyafaneleka yini ukwelashwa kwe-CAR-T. Lokhu kuzobandakanya ukubuyekezwa kwesimo somdlavuza sesiguli kanye nempilo yaso iyonke, kanye nokuqoqwa kwegazi ukuze kukhishwe amaseli e-T. Amaseli e-T aqoqiwe abe esethunyelwa elabhorethri yethu eqinisekiswe yi-GMP ukuze kuguqulwe izakhi zofuzo. Le nqubo ingathatha cishe amasonto ama-2-3.

4. Ukufakwa Kwamaseli Nokunakekelwa Kwangemva Kokwelashwa

Uma amaseli e-CAR-T aguquliwe eselungile, iziguli zizobuyela esibhedlela sethu ukuze ziyothola inqubo yokufaka. Lokhu ukwelashwa okwenziwa kanye kuphela lapho amaseli e-T aklanywe khona enikezwa ngemithambo yegazi. Ngemva kokufaka, iziguli zizohlala ziqashwe ngokucophelela izinsuku eziningana ukuze ziqaphele imiphumela emibi, njenge-cytokine release syndrome, okuyimpendulo engaba khona ekwelashweni. Ithimba lethu lezokwelapha linikeza ukwesekwa okuqhubekayo kanye nokuqapha phakathi nalesi sikhathi esibucayi.

Ngemva kokuphuma esibhedlela, i-BIOOCUS ihlela ukuvakasha okulandela njalo, okuhlanganisa ukuhlolwa kwelabhorethri kanye nezifundo zezithombe, ukuze kuqashwe ukusebenza kahle kokwelashwa nokulandelela ukululama kwesiguli. Iziguli zizoqashwa eduze ukuze kutholakale noma yimiphi imiphumela yamuva yokwelashwa, futhi ithimba lethu lizohlala lixhumana ukuze linikeze isiqondiso nokusekelwa okuqhubekayo.

Kwa-BIOOCUS, sibeka phambili impilo, ukuphepha, kanye nenduduzo yeziguli zethu zomhlaba wonke. Umgomo wethu ukuhlinzeka ngokunakekelwa okuphelele nokuqinisekisa ulwazi olusekelayo nolungenazihibe kulo lonke uhambo lokwelashwa lwe-CAR-T.

Ukuze uthole ulwazi olwengeziwe mayelana nezinsizakalo zethu nokuthi singakusiza kanjani ngokwelashwa kwakho, sicela usithinte ngqo.

incazelo2

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.